Nuclear export inhibitor Selinexor targeting XPO1 enhances coronavirus replication

• Published in: bioRxiv : the preprint server for biology
• Main Authors: Rahman, Masmudur M, Estifanos, Bereket, Glenn, Honor L, Kibler, Karen, Li, Yize, Jacobs, Bertram, McFadden, Grant, Hogue, Brenda G
• Format: Journal Article
• Language: English
• Published: United States 13.02.2023

Nucleocytoplasmic transport of proteins using XPO1 (exportin 1) plays a vital role in cell proliferation and survival. Many viruses also exploit this pathway to promote infection and replication. Thus, inhibiting XPO1-mediated nuclear export with selective inhibitors activates multiple antiviral and anti-inflammatory pathways. The XPO1 inhibitor, Selinexor, is an FDA-approved anticancer drug predicted to have antiviral function against many viruses, including SARS-CoV-2. Unexpectedly, we observed that pretreatment of cultured human cells with Selinexor actually enhanced protein expression and replication of coronaviruses, including SARS-CoV-2. Knockdown of cellular XPO1 protein expression significantly enhanced the replication of coronaviruses in human cells. We further demonstrate that Selinexor treatment reduced the formation of unique cytoplasmic antiviral granules that include RNA helicase DHX9 in the virus-infected cells. These results, for the first time, show that the anti-cancer drug Selinexor enhances the replication of coronaviruses in human cells and thus should be further explored for the potential impact on the dual use for anticancer and antiviral therapy.